Protagenic Therapeutics, Inc.\new Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
Protagenic Therapeutics, Inc.\new (PTIX) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of $1.35 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2018-05-15
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.35K.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $571.00.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $1.17K.
- Protagenic Therapeutics, Inc.\new available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2017 was -$1.43K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.35K 10-Q · filed 2018-05-15 | $1.92K derived: sum of 2 quarters · filed 2018-05-15 | $3.09K derived: sum of 3 quarters · filed 2018-05-15 | |
| 2017-12-31 | $571.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $1.74K derived: sum of 2 quarters · filed 2018-04-02 | -$1.43K 10-K · filed 2018-04-02 | |
| 2017-09-30 | $1.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$2.00K 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | -$3.16K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |